Skip to main content
CAI logo

CAI · Caris Life Sciences, Inc. · Holdings

Track CAI — free
$17.58 -0.96 (-5.18%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$5.04B
Shares
286.78M
Volume · Nov 20 4.57M Avg daily vol (3M) 4.64M

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 334
Total Value: $4,750,685,961
Total Shares: 155,099,124
Showing 1–100 of 341 holdings by value · page 1 of 4

Institutional Ownership Trend

6 quarters

A holder reported that quarter and withheld its positions under SEC confidential treatment, which is not a sale. The line counts it at the shares it last reported; filers usually disclose the real figures about a year later.

Holder Concentration

Share of 13F common-share value, across 334 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
24.7%
Jun 2025 → Sep 2026 · range 13.9% – 24.7%
+4.7 pts
Top 5
43.4%
Jun 2025 → Sep 2026 · range 43.4% – 52.8%
−0.3 pts
Top 10
56.9%
Jun 2025 → Sep 2026 · range 56.9% – 75.6%
−5.6 pts
HHI
777
Jun 2025 → Sep 2026 · range 660 – 870
Broadly held+116

Who Holds CAI

Last 6 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 330 filers, like-for-like change +0.8%; actively managed books +0.8%; index-like books +53.2%.

Holder type Share Filers Change
Registered adviser 36.4% 168 -2.3%
Exempt adviser 0.0% 2 -90.1%
Adviser 4.5% 11 -7.6%
Bank 7.1% 22 -2.4%
Broker-dealer 0.0% 1 -96.4%
Benefit plan 0.2% 6 +5.0%
Non-US 5.2% 11 +37.4%
Holding company 34.2% 9 +17.9%
Insurer 0.0% 0 —
Unknown 12.3% 100 -20.7%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-06-30 13F and 5 holders with no observed 2026-09-30 13F.

Conviction and Crowding

330 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
5
1.52% of filers hold it in their top 10
Jun 30, 2026: 6
Holders above 5%
3
median weight 0.006%
Jun 30, 2026: 3
Crowding
17.4%
of shares outstanding, 49th percentile
Jun 30, 2026: 18.1%
Private-fund advisers
14.1%
of shares outstanding
Institutional ownership
54.9%
190.3% of the estimated free float above 100%: filers can report lent or client shares more than once
Top 10 holders
56.9%
of 13F shares, Herfindahl 0.078
Active holders
+0.8%
like-for-like share change of active filers
5% stakes on record
2
0 13D, 2 13G (1 institutional, 0 passive, 1 exempt)
How long holders have held it value-weighted 4.7 quarters
Under 1 year 32.2% 1 to 3 years 67.8% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net sellers of $67,716,596 (10 buying, 9 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$22.18
estimated per share
Jun 30, 2026: $21.25
Quarter-end price
$30.63
implied by 13F values
Estimated gain or loss
+38.1%
price against the estimated cost
Estimated at a loss
0.086%
of costed 13F value

Estimated cost covers 39.2% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies CAI's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 CMPX Compass Therapeutics, Inc. 4
2 CLYM Climb Bio, Inc. 4
3 NKTR Nektar Therapeutics 6
4 SYRE Spyre Therapeutics, Inc. 6
5 RYTM Rhythm Pharmaceuticals, Inc. 6
6 ETRA Electra Therapeutics, Inc. 4
7 KRMN Karman Holdings Inc. 5
8 GLUE Monte Rosa Therapeutics, Inc. 4
9 VERA Vera Therapeutics, Inc. 5
10 ERAS Erasca, Inc. 5

Shareholder Targets

13F filers that own its peers but not CAI, quarter ended Sep 30, 2026

Found through its holder-overlap peers: CMPX, CLYM, NKTR, SYRE, RYTM, ETRA, KRMN, GLUE, VERA, ERAS, INSP, BBIO, MBX, LTGO, GKOS, IONS, ADRX, BRVE, GPCR, XFOR. 834 filers in all.

# Filer In peers
1 JANUS HENDERSON GROUP PLC Adviser, Diversified active $2,269,295,607 13 held
2 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $1,846,070,608 16 held
3 FARALLON CAPITAL MANAGEMENT LLC Registered adviser, Diversified active $976,383,715 4 held
4 Frazier Life Sciences Management, L.P. Registered adviser, Concentrated $940,377,142 4 held
5 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $930,382,220 5 held
6 PRIMECAP MANAGEMENT CO/CA/ Registered adviser, Diversified active $925,164,040 4 held
7 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $869,993,312 5 held
8 RTW INVESTMENTS, LP Registered adviser, Diversified active $746,784,020 5 held
9 BAKER BROS. ADVISORS LP Registered adviser, Concentrated $675,986,186 4 held
10 VIKING GLOBAL INVESTORS LP Registered adviser, Diversified active $644,328,010 1 held

Fund Ownership of CAI by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 4.70% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.47% 1,343,688
Index ETFs 4.24% 12,145,797
Active ETFs 0.05% 153,457
Active funds 15.81% 45,354,285
Unclassified 0.03% 76,069
All registered funds 20.60% 59,073,296
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
125
Increased
109
Decreased
69
Sold Out
39
Unchanged
29

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +83
Institutional value: +72.7%
Shares held: +0.4%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 341
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 341 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 2019410 CUSIP 142152107 13F (30d) 312 filings 296 filers Visit website Investor relations